Record Revenue Growth
Beta Bionics reported $23.2 million in net sales for Q2 2025, representing a 54% year-over-year increase.
Surge in New Patient Starts
4,934 new patients adopted the iLet in Q2 2025, growing 57% versus the prior year.
Pharmacy Channel Expansion
A high 20s percentage of new patient starts were reimbursed through the pharmacy channel, compared to a mid-single-digit percentage in Q2 of the prior year.
Improved Gross Margin
Gross margin for Q2 2025 was 53.8%, up slightly from 53.7% in Q2 2024, despite increased pharmacy channel costs.
Increased Annual Guidance
Full-year 2025 net sales guidance was raised to $88 million to $93 million from the prior $82 million to $87 million.